Targeting sphingosine kinase 1 localization as novel target for ovarian cancer therapy

Ovarian cancer represents the first cause of death for gynaecological malignancies in the western countries. Since specific and sensitive methods for early detection are missing, the large majority of patients are diagnosed at advanced stages (1). Aggressive chemotherapy with carboplatin and paclitaxel following surgery is initially efficacious, although most of the patients acquire chemoresistance and the clinical outcome in advanced ovarian cancer is very poor (1).